Related Experiment Video
Updated: Aug 7, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Treatment of anaerobic infections in children with metronidazole
Abstract:
The tolerance and efficacy of metronidazole were studied in 15 pediatric patients who had anaerobic infection. 5 had soft tissue abscess, 4 had aspiration pneumonia, 3 had intracranial abscess and 3 had chronic sinusitis. 45 bacterial isolates were recovered (3 isolates per patient). 40 were anaerobes and included 17 Bacteroides sp. (8 sp.), 16 anaerobic cocci and 6 Fusobacterium nucleatum. Metronidazole was given intravenously at the dose of 30 mg/kd/day or orally in the dose of 40-50 mg/kg/day. The length of therapy was between 14 and 52 days (average 26 days). 7 of the patients received initial parenteral therapy for 5-21 days (average 11.6 days), and subsequently received oral therapy. The minimal inhibitory concentration of 38 of the 41 anaerobic isolates (93%) was equal or less than 2 micrograms/ml. The mean peak concentration of metronidazole on the third day of therapy was 24.2 micrograms/ml range 15.2-30 micrograms/ml) and the mean trough was 7.2 micrograms/ml (range 4-11.6 micrograms/ml). No local or systemic adverse reaction as noted. A good response to therapy with a complete cure occurred in 14 of the 15 children. A fair response was achieved in 1 patient. Metronidazole appears to be effective and safe in the treatment of serious anaerobic infection in children.
Insights
Metronidazole demonstrated excellent safety and efficacy in treating serious anaerobic infections in pediatric patients. This antibiotic effectively cured 14 out of 15 children, showing minimal side effects.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Anaerobic infections pose significant challenges in pediatric care.
- Metronidazole is a key antibiotic for treating anaerobic bacterial infections.
Purpose of the Study:
- To evaluate the tolerance and efficacy of metronidazole in pediatric patients with anaerobic infections.
- To assess the safety profile and clinical outcomes of metronidazole therapy in children.
Main Methods:
- A study involving 15 pediatric patients diagnosed with anaerobic infections (abscesses, pneumonia, sinusitis).
- Administration of metronidazole intravenously (30 mg/kg/day) or orally (40-50 mg/kg/day) for 14-52 days.
- Analysis of bacterial isolates, minimal inhibitory concentrations (MICs), and drug concentration levels.
Main Results:
- 93% of anaerobic isolates had an MIC ≤ 2 µg/ml.
- Mean peak metronidazole concentration was 24.2 µg/ml, with a mean trough of 7.2 µg/ml.
- 14 of 15 children achieved a complete cure, with one showing a fair response; no adverse reactions were noted.
Conclusions:
- Metronidazole is a safe and effective treatment option for serious anaerobic infections in children.
- The drug achieved favorable pharmacokinetic profiles and clinical outcomes in the studied pediatric population.
Related Concept Videos
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Acute Pyelonephritis II: Diagnostic Studies and Management
Anthelminthic Agents
Antiprotozoal Agents

